Search Results

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it has successfully adapted and extended the use of its bioreactor capabilities for production of another clinically and commercially-important test-ingredient.

Microbix Biosystems Inc. reports results for its second quarter and first half of fiscal 2024 ended March 31, 2024.

Microbix Biosystems Inc. announces that its funding and commercialization partner, Sequel Pharma, LLC, has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization for production of the active ingredient of Kinlytic® urokinase, a biologic drug for dissolving blood clots.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that Labquality Ltd., a collaborator and customer, is presenting results of its use of Microbix Quality Assessment Products for accreditation of clinical labs for conducting molecular tests for antimicrobial-resistant strains of M. genitalium, a common sexually-transmitted infection.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its second quarter of fiscal 2024 ended March 31, 2024 prior to the start of trading on May 15, 2024.

Microbix Biosystems Inc. announces its hosting of Associate Minister of Small Business of Ontario, the Honourable Nina Tangri, to celebrate the opening of two expansions to its medical devices manufacturing capacity at one of its three adjacent Mississauga sites.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Center, North Building, on April 16 and 17, 2024.